COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Dec 12, 2022

Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

Sep 8, 2022

InvestmentPitch Media Video Discusses LOVE Pharma’s Strategic Investment in Starton Therapeutics, a New Jersey Based Clinical Stage Biotechnology Company

Jul 13, 2022

Starton Therapeutics Reports Positive Results from Phase 1 Study Evaluating STAR-LLD, Continuous Delivery Lenalidomide

May 23, 2022

Starton Therapeutics Announces Approval to Proceed with Final Dose Escalation in Phase 1 Clinical Study Evaluating STAR-LLD

May 23, 2022

Proactive news headlines including Twitter, Elon Musk, BioSig, Starton Therapeutics and Irwin Naturals

For More Press Releases

---